HALO

Halozyme Therapeutics, Inc.

HALAL

Score: 84/100

stock

Is HALO Halal?

Biopharma company that licenses its drug-delivery enzyme platform to partners and earns royalties — a permissible healthcare business, with convertible-note leverage as the primary financial-screen consideration.

What You Should Know

Halozyme Therapeutics, Inc. is a publicly-traded biopharmaceutical company whose principal business is licensing its proprietary ENHANZE drug-delivery technology — based on the recombinant human hyaluronidase enzyme that enables subcutaneous administration of partners' biologic drugs — to major pharmaceutical companies in exchange for royalties and milestone payments, alongside proprietary specialty products. Development and licensing of pharmaceutical drug-delivery technology is a permissible healthcare activity at the activity level under standard Sharia methodology. The financial screen is the primary consideration: Halozyme has issued convertible senior notes to fund growth and buybacks, so the debt-to-market-cap ratio should be verified against the 33% Sharia threshold at the time of investment, though the company is strongly profitable and generates substantial royalty-driven cash flow. Subject to that verification, most major Sharia advisory boards classify Halozyme as permissible with purification of small interest-income components.

⚠️ Concerns

•Debt-to-market-cap ratio should be verified against the 33% Sharia threshold at the time of investment — Halozyme has issued interest-bearing convertible senior notes; this is the primary Sharia-screening consideration, though the company is highly cash-generative
•Convertible notes are interest-bearing instruments — investors who object to any conventional-debt issuance should weigh this even where the debt ratio passes the 33% screen
•Interest income from cash balances should be checked against the 5% interest-income-to-revenue threshold and the relevant portion purified
•Royalty revenue is concentrated in a relatively small set of partner drugs, and a partner-patent or competitive event could affect results — this is a business consideration rather than a Sharia screen concern